Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight loss and diabetes drugs.
Recent Posts
- Some concertgoers use buy now, pay later loans for tickets. Start a ‘Beyoncé fund’ instead, analyst says
- Using my phone as a Paris guidebook cost me $50 — here’s how to save on your bill when traveling abroad
- Trump says he will meet with Putin in Alaska on Aug. 15
- Apple has its best week since July 2020 after White House visit
- Inflation data takes the spotlight next week on Wall Street